Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MVA-BN Filo vaccine

            Therapeutic Area: Infections and Infectious Diseases Product Name: MVA-BN-Filo

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Janssen Pharmaceutical

            Deal Size: $13.9 million Upfront Cash: Undisclosed

            Deal Type: Agreement June 18, 2020

            Details:

            Bavarian Nordic will manufacture and deliver bulk drug substance of its MVA-BN Filo vaccine, which Janssen has licensed as part of its Ebola vaccine regimen.